Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy postmenopausal women

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yuyu Pharma, Inc.
• Treatments: Alendronate; Calcitriol; Maxmarvil

Criteria

Inclusion Criteria:

• Screening test in healthy postmenopausal women without a previous history of fracture

• Normal range in laboratory test arranged by principal investigator because of the character of medicine

• over 50kg, body weight is in ± 20% of ideal body weight Written concent by himself and following the protocol after understanding of the explained clinical trial

Exclusion Criteria:

• Subject who have taken something to induce and inhibit the drug metabolizing enzyme within 1 month like Barbiturate.

• Subject who have a history of drug abuse and got a positive in urine test for drug abuse.

• Subject who have taken a prescription only medicine or an oriental medicine within 2 weeks after first administration the clinical drug trial , taken a OTC within 1 week after first administration the clinical drug trial like some OTC including calcium, an antacids, multiple vitamin, mineral.

• Subject who have been chronic drinking(over 21 units/week) or can not stop drinking during the clinical trial.

• Subject who have smoked over 10 unit/day for 3months.

• Subject who have light or clear hypersensitivity reaction about OTC(aspirin, antibiotic medication) or bisphosphonates(alendronate)

• Subject who have got a disease about liver, kidney, neurology, respiratory, endocrine, hematooncology, cardiovascular, musculoskeletal, psychological or history of fracture within 12months or a tooth extraction within 6month

• Subject who have a history of gastrointestinal disease or stomach surgery without appendectomy, herniotomy having an effort the absorb of clinical drug trial.

• Subject who have a esophageal disease like esophagitis, esophageal ulcer, esophagus erosion, esophagorrhaphy, esophagostenosis, dysphagia.

• Subject who can not keep the sitting position for 30minutes

• Subject who is out of normal range of calcium concentration in blood (8.8 ~ 10.5 mg/dl)

• Subject who is hypotension(systolic blood pressure ≤ 90mmHg or diastolic blood pressure ≤ 50 mmHg ) or hypertension(systolic blood pressure ≥ 150mmHg or diastolic blood pressure ≥ 100 mmHg ) in sitting position after rest 3 minutes

• join the other clinical trial within 2months after administration of the clinical drug trial.

• Subject who have donated whole blood within 2 months or plasma within 1 month.

• Subject who have a grapefruit and something including caffeine in close season(from 3 days before administration to discharge from the hospital )

• For the result of laboratory and the other reason subject is considered unsuitable by principal's decision